Table 4.

Net budgetary impact of ferric citrate vs. standard of care; one-way sensitivity analyses

	Net budgetary impact of ferric citrate vs. SOC (US$/year per 100 patients treated)
	Mean (SEM)	p valuea
Ratio of missed treatments to hospitalizations
1:1 (base case; 24% reduction in missed treatments)	+213,223 (14,111)	<0.001
1.25:1 (30% reduction in missed treatments)	+220,366 (14,340)	<0.001
1.5:1 (36% reduction in missed treatments)	+223,281 (14,839)	<0.001
Implications of Hb differential on ESA utilization, +0.35 g/dL greater Hb results in:
0% further reduction in ESA (base case)	+213,223 (14,111)	<0.001
10% further reduction in ESA	+246,690 (15,871)	<0.001
20% further reduction in ESA	+281,758 (19,262)	<0.001
30% further reduction in ESA	+316,296 (21,974)	<0.001

ESA erythropoiesis-stimulating agent, Hb hemoglobin, SEM standard error of mean, SOC standard of care

^a p value for comparison of mean, ferric citrate vs. SOC